Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Methicillin-Resistant Staphylococcus aureus | 28 | 2023 | 113 | 11.890 |
Why?
|
| Staphylococcal Infections | 29 | 2023 | 157 | 10.840 |
Why?
|
| Cross Infection | 28 | 2023 | 291 | 7.790 |
Why?
|
| Community-Acquired Infections | 13 | 2022 | 65 | 3.240 |
Why?
|
| Infection Control | 14 | 2023 | 166 | 3.120 |
Why?
|
| Bacteremia | 12 | 2019 | 97 | 3.100 |
Why?
|
| Genomics | 7 | 2022 | 53 | 1.680 |
Why?
|
| Chlorhexidine | 6 | 2021 | 63 | 1.650 |
Why?
|
| Staphylococcus aureus | 8 | 2023 | 69 | 1.480 |
Why?
|
| Sexual and Gender Minorities | 2 | 2021 | 23 | 1.340 |
Why?
|
| Humans | 49 | 2023 | 24703 | 1.130 |
Why?
|
| HIV Infections | 4 | 2013 | 433 | 1.110 |
Why?
|
| Catheterization, Central Venous | 3 | 2012 | 34 | 1.010 |
Why?
|
| Phenotype | 5 | 2021 | 280 | 0.990 |
Why?
|
| Staphylococcal Skin Infections | 4 | 2011 | 9 | 0.990 |
Why?
|
| Methicillin Resistance | 4 | 2012 | 25 | 0.940 |
Why?
|
| Anti-Infective Agents, Local | 4 | 2019 | 48 | 0.920 |
Why?
|
| Skin | 3 | 2014 | 116 | 0.870 |
Why?
|
| Carrier State | 4 | 2013 | 59 | 0.860 |
Why?
|
| Nasal Cavity | 2 | 2014 | 32 | 0.750 |
Why?
|
| Hospitals | 9 | 2023 | 149 | 0.730 |
Why?
|
| Soft Tissue Infections | 4 | 2011 | 25 | 0.720 |
Why?
|
| Skin Care | 2 | 2012 | 15 | 0.720 |
Why?
|
| Critical Care | 2 | 2014 | 112 | 0.710 |
Why?
|
| Baths | 2 | 2012 | 30 | 0.700 |
Why?
|
| Catheter-Related Infections | 4 | 2019 | 21 | 0.670 |
Why?
|
| Risk Factors | 9 | 2020 | 2099 | 0.610 |
Why?
|
| Hospital Administration | 6 | 2019 | 24 | 0.590 |
Why?
|
| Disease Outbreaks | 4 | 2023 | 74 | 0.590 |
Why?
|
| United States | 13 | 2023 | 1873 | 0.540 |
Why?
|
| Male | 15 | 2021 | 13669 | 0.530 |
Why?
|
| Intensive Care Units | 6 | 2021 | 246 | 0.510 |
Why?
|
| Anti-Bacterial Agents | 4 | 2021 | 362 | 0.490 |
Why?
|
| Bacterial Load | 2 | 2013 | 13 | 0.490 |
Why?
|
| Pneumonia, Staphylococcal | 2 | 2014 | 8 | 0.480 |
Why?
|
| Gram-Positive Bacteria | 2 | 2012 | 12 | 0.470 |
Why?
|
| Nose | 2 | 2013 | 32 | 0.470 |
Why?
|
| Virulence Factors | 1 | 2014 | 5 | 0.460 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 6 | 0.450 |
Why?
|
| Chicago | 6 | 2020 | 858 | 0.450 |
Why?
|
| Pharynx | 1 | 2014 | 11 | 0.450 |
Why?
|
| Quality Improvement | 3 | 2019 | 123 | 0.440 |
Why?
|
| Illinois | 3 | 2021 | 221 | 0.420 |
Why?
|
| Prisons | 1 | 2013 | 8 | 0.400 |
Why?
|
| Female | 13 | 2020 | 14048 | 0.400 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 4 | 2015 | 31 | 0.400 |
Why?
|
| HIV | 1 | 2012 | 39 | 0.370 |
Why?
|
| Inservice Training | 3 | 2019 | 25 | 0.360 |
Why?
|
| Equipment Contamination | 3 | 2019 | 24 | 0.350 |
Why?
|
| Disinfectants | 1 | 2010 | 7 | 0.350 |
Why?
|
| Homosexuality, Male | 2 | 2021 | 24 | 0.340 |
Why?
|
| Medical Staff, Hospital | 1 | 2010 | 16 | 0.330 |
Why?
|
| Prevalence | 3 | 2020 | 411 | 0.330 |
Why?
|
| Teaching Materials | 2 | 2019 | 8 | 0.320 |
Why?
|
| Disease Reservoirs | 1 | 2009 | 9 | 0.320 |
Why?
|
| Adult | 11 | 2021 | 7255 | 0.310 |
Why?
|
| Health Personnel | 2 | 2021 | 86 | 0.310 |
Why?
|
| Patient Safety | 2 | 2019 | 31 | 0.310 |
Why?
|
| Molecular Epidemiology | 2 | 2021 | 25 | 0.300 |
Why?
|
| Phylogeny | 2 | 2021 | 39 | 0.300 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2019 | 68 | 0.290 |
Why?
|
| Middle Aged | 10 | 2019 | 8294 | 0.280 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 130 | 0.270 |
Why?
|
| Prospective Studies | 4 | 2019 | 1612 | 0.270 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 245 | 0.270 |
Why?
|
| Genome, Bacterial | 2 | 2017 | 11 | 0.260 |
Why?
|
| Sequence Analysis, DNA | 2 | 2017 | 50 | 0.260 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2021 | 81 | 0.250 |
Why?
|
| DNA, Bacterial | 2 | 2017 | 36 | 0.250 |
Why?
|
| Hand Disinfection | 3 | 2019 | 25 | 0.240 |
Why?
|
| Technology | 1 | 2023 | 5 | 0.210 |
Why?
|
| Arizona | 1 | 2023 | 6 | 0.210 |
Why?
|
| Health Facilities | 1 | 2023 | 25 | 0.210 |
Why?
|
| Poisson Distribution | 2 | 2015 | 21 | 0.200 |
Why?
|
| Aged | 7 | 2019 | 8382 | 0.200 |
Why?
|
| Incidence | 6 | 2011 | 697 | 0.200 |
Why?
|
| Personal Protective Equipment | 2 | 2019 | 9 | 0.200 |
Why?
|
| Communicable Diseases | 2 | 2023 | 23 | 0.200 |
Why?
|
| Program Development | 2 | 2019 | 49 | 0.200 |
Why?
|
| Health Care Surveys | 2 | 2019 | 62 | 0.200 |
Why?
|
| Methicillin | 1 | 2021 | 6 | 0.180 |
Why?
|
| Molecular Typing | 1 | 2021 | 9 | 0.180 |
Why?
|
| Community Networks | 1 | 2021 | 4 | 0.180 |
Why?
|
| Mupirocin | 1 | 2021 | 17 | 0.180 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 304 | 0.170 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2010 | 12 | 0.160 |
Why?
|
| Antimicrobial Stewardship | 2 | 2019 | 18 | 0.160 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 2 | 0.160 |
Why?
|
| Stakeholder Participation | 1 | 2019 | 7 | 0.160 |
Why?
|
| Formative Feedback | 1 | 2019 | 3 | 0.160 |
Why?
|
| Organizational Objectives | 1 | 2019 | 12 | 0.160 |
Why?
|
| Patient Isolation | 1 | 2019 | 14 | 0.160 |
Why?
|
| Disinfection | 1 | 2019 | 10 | 0.160 |
Why?
|
| Clostridium Infections | 3 | 2019 | 24 | 0.160 |
Why?
|
| Protective Clothing | 1 | 2019 | 8 | 0.150 |
Why?
|
| Academic Medical Centers | 2 | 2010 | 117 | 0.150 |
Why?
|
| Medical Errors | 1 | 2019 | 25 | 0.150 |
Why?
|
| Research Personnel | 1 | 2018 | 16 | 0.150 |
Why?
|
| Curriculum | 1 | 2019 | 128 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2018 | 52 | 0.140 |
Why?
|
| Environmental Microbiology | 1 | 2017 | 5 | 0.140 |
Why?
|
| Bacteriological Techniques | 1 | 2017 | 14 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2017 | 37 | 0.140 |
Why?
|
| Risk Assessment | 1 | 2019 | 532 | 0.140 |
Why?
|
| Bacteria | 1 | 2017 | 59 | 0.140 |
Why?
|
| Physicians | 1 | 2018 | 103 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2017 | 3156 | 0.130 |
Why?
|
| Health Services Research | 1 | 2016 | 37 | 0.120 |
Why?
|
| Hospitals, Public | 1 | 2015 | 25 | 0.120 |
Why?
|
| Urban Health Services | 1 | 2015 | 12 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2015 | 34 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2015 | 73 | 0.120 |
Why?
|
| Culture Media | 2 | 2017 | 30 | 0.120 |
Why?
|
| Genetic Markers | 1 | 2014 | 33 | 0.110 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 86 | 0.110 |
Why?
|
| Comorbidity | 1 | 2015 | 447 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 53 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2015 | 315 | 0.110 |
Why?
|
| Bacterial Proteins | 1 | 2014 | 83 | 0.110 |
Why?
|
| International Classification of Diseases | 2 | 2011 | 13 | 0.100 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 39 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2010 | 3208 | 0.100 |
Why?
|
| Population Surveillance | 2 | 2010 | 106 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2012 | 123 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2012 | 240 | 0.090 |
Why?
|
| Clinical Coding | 1 | 2011 | 4 | 0.090 |
Why?
|
| Genotype | 1 | 2012 | 332 | 0.090 |
Why?
|
| Bacteriuria | 1 | 2010 | 4 | 0.090 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2010 | 6 | 0.080 |
Why?
|
| Military Personnel | 1 | 2010 | 37 | 0.080 |
Why?
|
| Soaps | 1 | 2010 | 8 | 0.080 |
Why?
|
| Geography | 1 | 2010 | 13 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2010 | 43 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2012 | 1748 | 0.080 |
Why?
|
| Gram-Negative Bacteria | 1 | 2009 | 23 | 0.080 |
Why?
|
| Blood | 1 | 2009 | 19 | 0.080 |
Why?
|
| Prognosis | 2 | 2010 | 674 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2010 | 144 | 0.080 |
Why?
|
| Sentinel Surveillance | 1 | 2009 | 7 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 61 | 0.080 |
Why?
|
| Data Collection | 1 | 2009 | 86 | 0.080 |
Why?
|
| Time Factors | 1 | 2012 | 1327 | 0.070 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 6 | 0.070 |
Why?
|
| Hygiene | 1 | 2008 | 10 | 0.070 |
Why?
|
| Drainage | 1 | 2008 | 41 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 412 | 0.060 |
Why?
|
| Young Adult | 3 | 2019 | 1847 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 12 | 0.050 |
Why?
|
| Quarantine | 1 | 2023 | 2 | 0.050 |
Why?
|
| Pandemics | 1 | 2023 | 190 | 0.050 |
Why?
|
| Child | 1 | 2023 | 1131 | 0.040 |
Why?
|
| Competency-Based Education | 1 | 2019 | 13 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2019 | 57 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2011 | 555 | 0.040 |
Why?
|
| Gloves, Protective | 1 | 2019 | 15 | 0.040 |
Why?
|
| Patient Discharge | 2 | 2010 | 143 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 63 | 0.040 |
Why?
|
| Family | 1 | 2019 | 90 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 116 | 0.040 |
Why?
|
| Training Support | 1 | 2018 | 4 | 0.040 |
Why?
|
| Career Choice | 1 | 2018 | 24 | 0.040 |
Why?
|
| Mentors | 1 | 2018 | 34 | 0.040 |
Why?
|
| Health Policy | 1 | 2018 | 35 | 0.040 |
Why?
|
| Societies, Scientific | 1 | 2018 | 4 | 0.040 |
Why?
|
| Universal Precautions | 1 | 2018 | 6 | 0.040 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2018 | 11 | 0.040 |
Why?
|
| Epidemiologists | 1 | 2017 | 1 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2017 | 4 | 0.040 |
Why?
|
| Public Health Practice | 1 | 2017 | 7 | 0.040 |
Why?
|
| Public Health Administration | 1 | 2017 | 9 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2018 | 118 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2017 | 33 | 0.030 |
Why?
|
| Enterobacteriaceae | 1 | 2018 | 40 | 0.030 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2018 | 54 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2016 | 18 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2016 | 26 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2016 | 24 | 0.030 |
Why?
|
| Adolescent | 2 | 2011 | 1992 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 244 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 4509 | 0.020 |
Why?
|
| Virulence | 1 | 2011 | 8 | 0.020 |
Why?
|
| Utah | 1 | 2011 | 1 | 0.020 |
Why?
|
| Baltimore | 1 | 2011 | 10 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 51 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2011 | 42 | 0.020 |
Why?
|
| Biological Assay | 1 | 2010 | 5 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 437 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2009 | 22 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 234 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 384 | 0.020 |
Why?
|